Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anil Purohit

Clinical Cardiac Electrophysiology Indianapolis, IN Medical Doctor

NPI 1255541835 CMS profile 238113

1402 E County Line Rd, Indianapolis, IN 46227

Open in the dashboard

General payments

$44,776

555 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anil Purohit of Indianapolis, IN is reported in the CMS Open Payments database as having received $44,776 across 555 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,454 84
2024 General $12,704 80
2023 General $8,600 112
2022 General $1,916 71
2021 General $1,757 47
2020 General $2,408 33
2019 General $7,936 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anil Purohit
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Anil Purohit were reported at $9,454. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Anil Purohit Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,936 $2,361 $585–$8,260 $163
2020 $2,408 $993 $247–$4,351 $114
2021 $1,757 $1,185 $326–$4,739 $132
2022 $1,916 $2,073 $554–$6,789 $149
2023 $8,600 $2,568 $759–$8,159 $160
2024 $12,704 $2,557 $703–$7,403 $164
2025 $9,454 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $20,044 79 payments
  2. Boston Scientific Corporation $7,979 161 payments
  3. Medtronic, Inc. $5,758 35 payments
  4. Medtronic Vascular, Inc. $4,366 25 payments
  5. Abbott Laboratories $3,044 107 payments
  6. CardioFocus, Inc. $777 6 payments
  7. Janssen Pharmaceuticals, Inc $651 28 payments
  8. Pfizer Inc. $373 25 payments
  9. Sanofi-Aventis U.S. LLC $280 18 payments
  10. Amgen Inc. $208 13 payments
  11. Other $1,295 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $18,982 35 payments
  2. Food and Beverage $18,348 515 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,976 1 payment
  4. Compensation for serving as faculty or as a speaker for a medical education program $2,800 2 payments
  5. Consulting Fee $1,600 1 payment
  6. Education $70 1 payment
Products named General payments · program years 2019–2025
  1. Solia $8,086 12 payments
  2. Selectra $7,896 11 payments
  3. Arctic Front $4,222 22 payments
  4. Edora 8 DR-T $1,615 2 payments
  5. General - Therapies General - Therapies_Non Divisional $1,308 5 payments
  6. ENSITE $712 12 payments
  7. WATCHMAN Access System $698 13 payments
  8. XARELTO $651 28 payments
  9. Micra $404 9 payments
  10. General - Therapies General - Therapies_CRM $395 8 payments
  11. Other $11,979 401 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

3,090

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,328,639

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

48.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 728 $916,077
Xarelto Rivaroxaban Brand 253 $283,424
Multaq Dronedarone Hcl Brand 42 $51,277
Dofetilide Generic 156 $34,712
Metoprolol Succinate Generic 599 $7,599
Sotalol Sotalol Hcl Brand 284 $5,881
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 12 $5,412
Flecainide Acetate Generic 93 $4,324
Mexiletine Hcl Generic 38 $3,761
Amiodarone Hcl Generic 178 $3,225

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$294,948

Medicare's payments for the services billed

Medicare patients

785

Average age 78

Services billed

4,857

391 women, 394 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 67%
Ischemic heart disease 55%
Heart failure 52%
Arthritis 44%
Diabetes 40%
Chronic kidney disease 39%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $35
$35 728 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $32
$32 42 —
VYNDAQEL
  • PFIZER INC. $23
$23 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $14
$14 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $14
$14 253 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

555 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record